Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.37 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.37 |
| ▸ | HK2 | P52789 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18713910 | 1.00 | SMN1; SMN2 (0.40) | SMN1; SMN2PTGS2KDM4EHPGDCYP1A2 | |
| SCHEMBL18529211 | 0.82 | PTGS2 (0.43) | SMN1; SMN2PTGS2KDM4EHPGDNPC1 | |
| SCHEMBL18530070 | 0.82 | ALDH1A1 (0.43) | PTGS2KDM4EHPGDKMT2AMEN1 | |
| SCHEMBL2886215 | 0.80 | HPGD (0.49) | KDM4EHPGDKMT2AMEN1MAPT | |
| SCHEMBL4973152 | 0.78 | SMN1; SMN2 (0.40) | SMN1; SMN2PTGS2KDM4EHPGDCYP1A2 | |
| SCHEMBL21543537 | 0.76 | CA1 (0.37) | KMT2AMEN1MAPTMAPK1POLB | |
| SCHEMBL18529189 | 0.76 | HCAR2 (0.38) | SMN1; SMN2CYP1A2HCAR2HCAR3NPC1 | |
| SCHEMBL8709953 | 0.72 | CFTR (0.43) | SMN1; SMN2KDM4EHPGDCYP1A2HCAR2 | |
| SCHEMBL4650543 | 0.68 | SMN1; SMN2 (0.38) | SMN1; SMN2KDM4EHPGDHK2KMT2A | |
| SCHEMBL11800450 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11401240-B2 | Process for the synthesis of lactams | CONOPCO, INC. (US) | 2022-08-02 | — | — | US | disclosed |
| US-20210395199-A1 | PROCESS FOR THE SYNTHESIS OF LACTAMS | CONOPCO, INC., D/B/A UNILEVER (US) | 2021-12-23 | — | — | US | disclosed |
| US-10377707-B2 | Process for the preparation of lactams from glyoxalic acid | CONOPCO INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20170096391-A1 | NOVEL LACTAMS | BIOSIGNAL LIMITED (AU) | 2017-04-06 | — | — | US | disclosed |
| US-20170096391-A1 | NOVEL LACTAMS | BIOSIGNAL LIMITED (AU) | 2017-04-06 | — | — | US | disclosed |
| US-20170096391-A1 | NOVEL LACTAMS | BIOSIGNAL LIMITED (AU) | 2017-04-06 | — | — | US | disclosed |
| US-9586901-B2 | Lactams | UNILEVER PLC (GB) | 2017-03-07 | — | — | US | disclosed |
| US-9586901-B2 | Lactams | UNILEVER PLC (GB) | 2017-03-07 | — | — | US | disclosed |
| US-9586901-B2 | Lactams | UNILEVER PLC (GB) | 2017-03-07 | — | — | US | disclosed |
| US-20130190377-A1 | Novel Lactams | BIOSIGNAL LIMITED (AU) | 2013-07-25 | — | — | US | disclosed |
| US-20130190377-A1 | Novel Lactams | BIOSIGNAL LIMITED (AU) | 2013-07-25 | — | — | US | disclosed |
| EP-1981844-A1 | NOVEL LACTAMS | Biosignal Limited (AU) | 2008-10-22 | — | — | EP | disclosed |
| EP-1294705-B1 | SYNTHESIS OF CYCLIC COMPOUNDS | BIOSIGNAL LTD (AU) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007085042-A1 | NOVEL LACTAMS | BIOSIGNAL LIMITED (AU) | 2007-08-02 | — | — | WO | disclosed |
| US-6958145-B2 | Synthesis of cyclic compounds | UNISEARCH LIMITED (AU) | 2005-10-25 | — | — | US | disclosed |
| US-20050215772-A1 | Furanone derivatives and methods of making same | BIOSIGNAL LIMITED (AT) | 2005-09-29 | — | — | US | disclosed |
| EP-1539692-A4 | FURANONE DERIVATIVES AND METHODS OF MAKING SAME | BIOSIGNAL LTD (AU) | 2005-08-24 | — | — | EP | disclosed |
| EP-1539692-A1 | FURANONE DERIVATIVES AND METHODS OF MAKING SAME | Biosignal Limited (AU) | 2005-06-15 | — | — | EP | disclosed |
| US-20040110966-A1 | Synthesis of cyclic compounds | UNISEARCH LIMITED (AU) | 2004-06-10 | — | — | US | disclosed |
| WO-2004016588-A1 | FURANONE DERIVATIVES AND METHODS OF MAKING SAME | BIOSIGNAL LIMITED (AU) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190377-A1 | Novel Lactams | SULT1E1, PGLS, Q6ZSR9 | SMN1; SMN2 3847/4885PTGS2 3043/4885KDM4E 828/4885 |
| US-20170096391-A1 | NOVEL LACTAMS | SULT1E1, PGLS, Q6ZSR9 | SMN1; SMN2 3847/4885PTGS2 3043/4885KDM4E 828/4885 |
| US-20050215772-A1 | Furanone derivatives and methods of making same | PFAS, CFAP20, FDPS | SMN1; SMN2 4604/4885PTGS2 358/4885KDM4E 2524/4885 |
| US-11401240-B2 | Process for the synthesis of lactams | COASY, PGLS, SBDS | SMN1; SMN2 4355/4885PTGS2 2440/4885KDM4E 1757/4885 |
| US-10377707-B2 | Process for the preparation of lactams from glyoxalic acid | GLO1, PGLS, GRHPR | SMN1; SMN2 4711/4885PTGS2 929/4885KDM4E 1103/4885 |
| US-20210395199-A1 | PROCESS FOR THE SYNTHESIS OF LACTAMS | COASY, PGLS, SBDS | SMN1; SMN2 4355/4885PTGS2 2440/4885KDM4E 1757/4885 |
| US-20040110966-A1 | Synthesis of cyclic compounds | RFC2, POLR2H, REV1 | SMN1; SMN2 4466/4885PTGS2 3304/4885KDM4E 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.